Tango Therapeutics, Inc. Lessee, Operating Lease, Liability, Undiscounted Excess Amount
Tango Therapeutics, Inc. (TNGX) had Lessee, Operating Lease, Liability, Undiscounted Excess Amount of $10.80 million as of 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Notes › Leases
us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount · last filed 2026-03-05
- 2025-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $10.80M.
- 2023-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $13.61M; Lessee, Operating Lease, Liability, Undiscounted Excess Amount as first filed $16.62M.
- 2022-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $20.12M.
- 2021-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $69.00K.
| Period end | Lessee, Operating Lease, Liability, Undiscounted Excess Amount | Lessee, Operating Lease, Liability, Undiscounted Excess Amount as first filed |
|---|---|---|
| 2025-12-31 | $10.80M 10-K · filed 2026-03-05 | |
| 2023-12-31 | $13.61M 10-K · filed 2025-02-27 | $16.62M 10-K · filed 2024-03-18 |
| 2022-12-31 | $20.12M 10-K · filed 2023-03-27 | |
| 2021-12-31 | $69.00K 10-K · filed 2022-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |